Cargando…

Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis

Immune checkpoint inhibitors, such as ipilimumab (an anti-CTLA4 antibody), have become a commonly used therapy in cancer. To date, safety data of patients with underlying autoimmune disease is limited. We present a case of a patient with rheumatoid arthritis who was diagnosed of a BRAF-mutant metast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aya, Francisco, Gaba, Lydia, Victoria, Ivan, Fernandez-Martinez, Aranzazu, Ruiz-Esquide, Virginia, Pineda, Estela, Tosca, Monica, Viladot, Margarita, Pereira, Veronica, Malvehy, Josep, Prat, Aleix, Arance, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070207/ https://www.ncbi.nlm.nih.gov/pubmed/27843587 http://dx.doi.org/10.1136/esmoopen-2015-000032

Ejemplares similares

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy
por: Prat, Aleix, et al.
Publicado: (2015)

Infectious Colitis Associated With Ipilimumab Therapy
por: McCutcheon, Jessica L., et al.
Publicado: (2014)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma(☆)
por: Tarhini, A.A., et al.
Publicado: (2021)

Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma
por: Rabinowitz, Matthew J., et al.
Publicado: (2020)

Ipilimumab-Induced Enteritis without Colitis: A New Challenge
por: Messmer, Marcus, et al.
Publicado: (2016)

Ipilimumab as a Cause of Severe Pan-Colitis and Colonic Perforation
por: Shah, Raj, et al.
Publicado: (2017)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
por: Dalle, Stéphane, et al.
Publicado: (2021)

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis
por: Arriola, Edurne, et al.
Publicado: (2016)

Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
por: Anson, David, et al.
Publicado: (2019)

Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma
por: Moein, Hamid-Reza, et al.
Publicado: (2021)

Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program
por: Berrocal, Alfonso, et al.
Publicado: (2014)

Late Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complication
por: Yun, Seongseok, et al.
Publicado: (2015)

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
por: Amin, Asim, et al.
Publicado: (2016)

Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
por: Myrdal, Caitlyn N., et al.
Publicado: (2020)

Ipilimumab
Publicado: (2012)

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134
por: Atkins, Michael B., et al.
Publicado: (2023)

Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival
por: Villa-Crespo, Lorena, et al.
Publicado: (2022)

Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report
por: Nassri, Ammar B, et al.
Publicado: (2019)

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
por: Nahar, Kazi J, et al.
Publicado: (2020)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
por: Moser, Justin C., et al.
Publicado: (2019)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)
por: McArthur, Grant A., et al.
Publicado: (2017)

Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response
por: Gonzalez-Cao, Maria, et al.
Publicado: (2016)

Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence
por: ERTEKIN, Sümeyre Seda, et al.
Publicado: (2021)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
por: Bostwick, A Doran, et al.
Publicado: (2015)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Lau, Peter Kar Han, et al.
Publicado: (2021)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy
por: Kuang, Andrew G., et al.
Publicado: (2023)

Use of ipilimumab in the treatment of melanoma
por: Acharya, Utkarsh H, et al.
Publicado: (2013)

Ipilimumab-induced colonic perforation
por: Burdine, Lyle, et al.
Publicado: (2014)

Ipilimumab-Induced Neutropenia in Melanoma
por: Ban-Hoefen, Makiko, et al.
Publicado: (2016)

Ipilimumab induced digital vasculitis
por: Padda, Amrita, et al.
Publicado: (2018)

Mucosal‐associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy‐related colitis in a pathology distinct from ulcerative colitis
por: Sasson, S. C., et al.
Publicado: (2020)

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
por: Gonzalez-Cao, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jml09jgv226th5usrcdsvvgf6r